BlueGnome used this weekend’s conference of the Chinese Society of Reproductive Medicine in Chongqing to announce the availability of its 24sure and CytoChip platforms in China. Both 24sure and CytoChip combine advanced microarray technology with sophisticated signal processing software in order to inform investigation of genetic disorders from cancer to infertility.

The application of 24sure to the investigation of IVF failure and recurrent miscarriage will be presented to the largely Chinese audience by Dr Leeanda Wilton, a leader in the field, who is performing pioneering work with 24sure in her laboratory at Melbourne IVF in Australia.

Speaking at the event Dr Tony Gordon, Director of 24sure at BlueGnome, explained. “China represents a substantial market for our unique range of technologies. Having established a presence throughout South East Asia and Japan it was important for us to develop a presence in China. In order to achieve this we have been working very close with Dr Dunsong Yang and his colleagues at Shishou Kangxin Trading Co to develop closer links with investigators in China. As a result of this we are happy to announce the first shipments of 24sure and CytoChip into mainland China.”

The launch in China follows closely on the recent announcement of BlueGnome’s CytoChip Cancer platform. Commenting on these developments Dr Nick Haan, CEO BlueGnome, stated “BlueGnome’s unique combination of advanced mathematics and molecular biology, combined with very close links with leading laboratories in over 35 countries, is enabling us to help customers in more and more geographies investigate an ever broadening range of conditions with a genetic basis.”

About BlueGnome

BlueGnome is a specialist developer of microarray based solutions for the investigation of chromosomal abnormalities in cytogenetics and IVF. BlueGnome microarrays are for research use only.